Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Durvalumab vs Standard of Care in First-Line Advanced NSCLC
NCT03003962Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2017
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Arm 1: Durvalumab with Arm 2: Standard of Care (2 arms). Primary endpoints: Overall Survival at 69 months and Overall Survival in Participants With Low Risk of Early Mortality at 69 months. Started Jan 2017; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03003962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003962.